 Jessica Borgers
Concepts (83)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 8 | 2025 | 730 | 2.950 |
Why?
| | Cell- and Tissue-Based Therapy | 3 | 2022 | 75 | 1.430 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2024 | 211 | 1.080 |
Why?
| | Neoplasms, Second Primary | 2 | 2023 | 106 | 0.930 |
Why?
| | Antigens, Neoplasm | 2 | 2025 | 309 | 0.920 |
Why?
| | Seroconversion | 1 | 2024 | 46 | 0.890 |
Why?
| | Myocarditis | 1 | 2024 | 98 | 0.810 |
Why?
| | Immunotherapy, Adoptive | 2 | 2022 | 295 | 0.710 |
Why?
| | Precision Medicine | 1 | 2025 | 387 | 0.710 |
Why?
| | Splenectomy | 1 | 2020 | 58 | 0.660 |
Why?
| | Immune Tolerance | 1 | 2021 | 355 | 0.640 |
Why?
| | T-Lymphocytes | 2 | 2025 | 1928 | 0.620 |
Why?
| | Immunotherapy | 1 | 2021 | 592 | 0.550 |
Why?
| | Autoantibodies | 1 | 2024 | 1466 | 0.520 |
Why?
| | Skin Neoplasms | 2 | 2024 | 825 | 0.510 |
Why?
| | Neoplasms | 4 | 2023 | 2470 | 0.480 |
Why?
| | Cytokines | 1 | 2020 | 2017 | 0.400 |
Why?
| | Interleukin-2 | 2 | 2024 | 436 | 0.350 |
Why?
| | Retrospective Studies | 5 | 2024 | 14518 | 0.260 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2024 | 232 | 0.240 |
Why?
| | Vaccines, DNA | 1 | 2024 | 28 | 0.220 |
Why?
| | Tattooing | 1 | 2024 | 14 | 0.220 |
Why?
| | Aged, 80 and over | 4 | 2024 | 7086 | 0.210 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 72 | 0.200 |
Why?
| | Aged | 6 | 2025 | 22103 | 0.200 |
Why?
| | Gastroenteritis | 1 | 2023 | 67 | 0.200 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2022 | 50 | 0.200 |
Why?
| | Fecal Microbiota Transplantation | 1 | 2022 | 21 | 0.200 |
Why?
| | Humans | 14 | 2025 | 129650 | 0.200 |
Why?
| | Cancer Vaccines | 1 | 2024 | 164 | 0.200 |
Why?
| | Neoplasm Metastasis | 1 | 2025 | 610 | 0.200 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2023 | 181 | 0.190 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2023 | 64 | 0.190 |
Why?
| | Survival Rate | 2 | 2023 | 1877 | 0.190 |
Why?
| | Life Support Care | 1 | 2021 | 30 | 0.180 |
Why?
| | Withholding Treatment | 1 | 2021 | 71 | 0.180 |
Why?
| | Cell Engineering | 1 | 2020 | 9 | 0.180 |
Why?
| | Seasons | 1 | 2023 | 502 | 0.180 |
Why?
| | Middle Aged | 6 | 2025 | 31154 | 0.180 |
Why?
| | Receptors, CCR | 1 | 2020 | 8 | 0.170 |
Why?
| | Neoplasm Staging | 1 | 2024 | 1295 | 0.170 |
Why?
| | Platelet Count | 1 | 2020 | 82 | 0.170 |
Why?
| | Feces | 1 | 2022 | 440 | 0.160 |
Why?
| | Basophils | 1 | 2020 | 73 | 0.160 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 84 | 0.160 |
Why?
| | Mortality | 1 | 2021 | 307 | 0.160 |
Why?
| | Leukocyte Count | 1 | 2020 | 326 | 0.160 |
Why?
| | Postoperative Period | 1 | 2020 | 329 | 0.150 |
Why?
| | Myeloid Cells | 1 | 2020 | 143 | 0.150 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 159 | 0.150 |
Why?
| | Genetic Therapy | 1 | 2020 | 292 | 0.150 |
Why?
| | Adult | 5 | 2025 | 35576 | 0.150 |
Why?
| | Lymphocytes | 1 | 2020 | 377 | 0.140 |
Why?
| | Female | 7 | 2025 | 68776 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2022 | 1368 | 0.130 |
Why?
| | Monocytes | 1 | 2020 | 551 | 0.130 |
Why?
| | Survival Analysis | 1 | 2020 | 1274 | 0.130 |
Why?
| | Disease Progression | 1 | 2024 | 2635 | 0.130 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2020 | 704 | 0.130 |
Why?
| | Male | 6 | 2025 | 63681 | 0.120 |
Why?
| | Hospitalization | 1 | 2021 | 2070 | 0.100 |
Why?
| | Treatment Outcome | 2 | 2024 | 10230 | 0.090 |
Why?
| | Pregnancy | 1 | 2021 | 6402 | 0.080 |
Why?
| | Biomarkers | 1 | 2020 | 3973 | 0.080 |
Why?
| | MART-1 Antigen | 1 | 2024 | 12 | 0.060 |
Why?
| | Injections, Intradermal | 1 | 2024 | 13 | 0.060 |
Why?
| | HLA-A2 Antigen | 1 | 2024 | 48 | 0.060 |
Why?
| | Diarrhea, Infantile | 1 | 2023 | 8 | 0.060 |
Why?
| | Enterocolitis | 1 | 2023 | 17 | 0.050 |
Why?
| | Failure to Thrive | 1 | 2023 | 29 | 0.050 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2024 | 186 | 0.050 |
Why?
| | Ipilimumab | 1 | 2022 | 31 | 0.050 |
Why?
| | Enteritis | 1 | 2023 | 93 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 130 | 0.050 |
Why?
| | Netherlands | 1 | 2021 | 77 | 0.050 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2023 | 759 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 857 | 0.040 |
Why?
| | Vaccination | 1 | 2024 | 1348 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1565 | 0.030 |
Why?
| | Prognosis | 1 | 2021 | 3794 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 5420 | 0.020 |
Why?
| | Infant | 1 | 2023 | 9024 | 0.020 |
Why?
| | Risk Factors | 1 | 2021 | 9765 | 0.020 |
Why?
|
|
Borgers's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|